Search Results - "Meca Lallana, José E."

Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study by Millán-Pascual, Jorge, Valero-López, Gabriel, Iniesta-Martinez, Francisca, Hellin-Gil, Maria Fuensanta, Jimenez-Veiga, Judith, López-Tovar, Isabel Alejandra, Morales-Ortiz, Ana, Meca-Lallana, José. E.

“…Introduction The risk of SARS-CoV-2 infection or severe coronavirus disease 2019 (COVID-19) has been shown to increase in patients with multiple sclerosis…”
Get full text

Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire by Meca-Lallana, José E, Maurino, Jorge, Pérez-Miralles, Francisco, Forero, Lucía, Sepúlveda, María, Calles, Carmen, Martínez-Ginés, María L, González-Suárez, Inés, Boyero, Sabas, Romero-Pinel, Lucía, Sempere, Ángel P, Meca-Lallana, Virginia, Querol, Luis, Costa-Frossard, Lucienne, Prefasi, Daniel, Gómez-Ballesteros, Rocío, Ballesteros, Javier

“…The assessment of self-reported outcomes in neuromyelitis optica spectrum disorder (NMOSD) is limited by the lack of validated disease-specific measures. The…”
Get full text

Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management by Oreja-Guevara, Celia, Martínez-Yélamos, Sergio, Eichau, Sara, Llaneza, Miguel Ángel, Martín-Martínez, Jesús, Peña-Martínez, Joaquín, Meca-Lallana, Virginia, Alonso-Torres, Ana María, Moral-Torres, Ester, Río, Jordi, Calles, Carmen, Ares-Luque, Adrián, Ramió-Torrentà, Lluís, Marzo-Sola, María Eugenia, Prieto, José María, Martínez-Ginés, María Luisa, Arroyo, Rafael, Otano-Martínez, María Ángeles, Brieva-Ruiz, Luis, Gómez-Gutiérrez, Montserrat, Rodríguez-Antigüedad, Alfredo, Galán Sánchez-Seco, Victoria, Costa-Frossard, Lucienne, Hernández-Pérez, Miguel Ángel, Landete-Pascual, Lamberto, González-Platas, Montserrat, Meca-Lallana, José E

“…Recent advances in multiple sclerosis (MS) management have shifted perspectives on treatment strategies, advocating for the early initiation of high-efficacy…”
Get full text

Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study by Coyle, Patricia K., Khatri, Bhupendra, Edwards, Keith R., Meca-Lallana, José E., Cavalier, Steve, Rufi, Pascal, Benamor, Myriam, Brette, Sandrine, Robinson, Miqun, Gold, Ralf

“…Patient-reported outcomes (PROs) provide clinicians with further understanding of the impact of treatment on patients’ daily lives. In addition, real-world…”
Get full text

Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice by Coyle, Patricia K., Khatri, Bhupendra, Edwards, Keith R., Meca-Lallana, José E., Cavalier, Steve, Rufi, Pascal, Benamor, Myriam, Thangavelu, Karthinathan, Robinson, Miqun, Gold, Ralf

“…•Teri-PRO patients who switched DMT reported high levels of treatment satisfaction.•This was observed regardless of reason for treating with…”
Get full text

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus by Sepúlveda, Maria, Armangué, Thaís, Sola-Valls, Nuria, Arrambide, Georgina, Meca-Lallana, José E, Oreja-Guevara, Celia, Mendibe, Mar, Alvarez de Arcaya, Amaya, Aladro, Yolanda, Casanova, Bonaventura, Olascoaga, Javier, Jiménez-Huete, Adolfo, Fernández-Fournier, Mireya, Ramió-Torrentà, Lluis, Cobo-Calvo, Alvaro, Viñals, Montserrat, de Andrés, Clara, Meca-Lallana, Virginia, Cervelló, Angeles, Calles, Carmen, Rubio, Manuel Barón, Ramo-Tello, Cristina, Caminero, Ana, Munteis, Elvira, Antigüedad, Alfredo R, Blanco, Yolanda, Villoslada, Pablo, Montalban, Xavier, Graus, Francesc, Saiz, Albert, Borrego, Laura, Villaverde, Francisco José J, Sempere, Ángel P, Brieva, Luis, Bonet, Macarena, González-Platas, Montserrat, Puma, Delon La, Llufriu, Sara, Martínez, Eugenia H, Boyero, Sabas, Benito-León, Julián, López, Juan C, Robles, René, Foronda, Jesús, Navarró, Laura, Millán, Tomás, Hervás, Miguel, Tallón, Antonio, Puertas, Inmaculada, Huertas, Nuria, Redondo, Laura, Santos, Sonia, Palmí, Itziar, Salgado, Mónica, Martínez, José E, Rubio, Miguel A, Oterino, Agustín, Ara, Ramón, Villaverde, Ramón, Ayuso, Teresa, Erro, Elena, Marco, Miquel, Villar, Luisa, Álvarez-Cermeño, José C, Agüera, Eduardo, Bescansa, Enrique, Yugüeros, Isabel, Tola, Miguel A, Orviz-García, Aida, del Haro, Tomás, Bestué, María, Gómez, Monserrat, Querol, Luis, Rodríguez, Elena, Ballabriga, Jordi, Tintoré, Mar, Castilló, Joaquin, Rio, Jordi, Muñoz, Delicias, Midaglia, Luciana, Carreón-Guarnizo, Ester, Casado, José L, Uclés, Antonio, García-Montero, Rosa

“…OBJECTIVE:To (1) determine the value of the recently proposed criteria of neuromyelitis optica (NMO) spectrum disorder (NMOSD) that unify patients with NMO and…”
Get full text

SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry by Arrambide, Georgina, Llaneza-González, Miguel Ángel, Costa-Frossard França, Lucienne, Meca-Lallana, Virginia, Díaz, Eva Fernández, Moreno-Torres, Irene, García-Domínguez, Jose Manuel, Ortega-Suero, Gloria, Ayuso-Peralta, Lucía, Gómez-Moreno, Mayra, Sotoca-Fernández, Javier J., Caminero-Rodríguez, Ana Belén, Rodríguez de Antonio, Luis A., Corujo-Suárez, Marcial, Otano-Martínez, María A., Pérez-Miralles, Francisco Carlos, Reyes-Garrido, Virginia, Ayuso-Blanco, Teresa, Balseiro-Gómez, José Jesús, Muñoz-Pasadas, Mercedes, Pérez-Molina, Inmaculada, Arnal-García, Carmen, Domingo-Santos, Ángela, Guijarro-Castro, Cristina, Íñiguez-Martínez, Cristina, Téllez Lara, Nieves, Castellanos-Pinedo, Fernando, Castillo-Triviño, Tamara, Cerdán-Santacruz, Debora María, Pérez-Sempere, Ángel, Torres, Berta Sebastián, Álvarez de Arcaya, Amaya, Costa-Arpín, Eva, Durán-Ferreras, Eduardo, Fragoso-Martínez, Marta, González-Platas, Montserrat, Landete Pascual, Lamberto, Millán-Pascual, Jorge, Oreja-Guevara, Celia, Meca-Lallana, José E.

“…OBJECTIVETo understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state…”
Get full text

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study by Oreja-Guevara, Celia, Meca-Lallana, José E., Díaz-Díaz, Judit, Ara, José-Ramón, Hernández Pérez, Miguel Ángel, Gracia Gil, Julia, Alonso Torres, Ana María, Pilo de la Fuente, Belén, Ramió-Torrentà, Lluís, Eichau Madueño, Sara, Gascón-Giménez, Francisco, Casanova, Bonaventura, Martínez-Yélamos, Sergio, Aguado Valcárcel, Marta, Martínez Ginés, Maria Luisa, El Berdei Montero, Yasmina, López Real, Ana María, González-Quintanilla, Vicente, De Torres, Laura, Martínez-Rodríguez, José Enrique, Costa-Frossard, Lucienne, Garcés Redondo, Moisés, Labiano Fontcuberta, Andrés, Castellanos-Pinedo, Fernando, García Merino, Juan Antonio, Muñoz Fernández, Carmen, Castillo-Triviño, Tamara, Meca-Lallana, Virginia, Peña Martínez, Joaquín, Rodríguez-Antigüedad, Alfredo, Prieto González, José María, Agüera Morales, Eduardo, Pérez Molina, Inmaculada, Solar Sánchez, Dulce M, Herrera Varo, Nicolás, Romero Sevilla, Raúl, Gómez Vicente, Lidia, Río, Jordi

“…•SPMS represents a considerable negative impact on patients’ HRQoL•Unfortunately, there is a lack of data about the impact of SPMS disability on HRQoL•DISCOVER…”
Get full text

Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30) by Valero-López, Gabriel, Millán-Pascual, Jorge, Iniesta-Martínez, Francisca, Delgado-Marín, Juan L., Jimenez-Veiga, Judith, Tejero-Martín, Ana B., León-Hernández, Adelaida, Zamarro-Parra, Joaquín, Morales-Ortiz, Ana, Meca-Lallana, José E.

“…•Treatment with natalizumab during pregnancy requires careful management.•The NAP-30 protocol is designed to maintain natalizumab efficacy and safety during…”
Get full text

Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study by Meca-Lallana, José E., Gómez-Ballesteros, Rocío, Pérez-Miralles, Francisco, Forero, Lucía, Sepúlveda, María, Calles, Carmen, Martínez-Ginés, María L., González-Suárez, Inés, Boyero, Sabas, Romero-Pinel, Lucía, Sempere, Ángel P., Meca-Lallana, Virginia, Querol, Luis, Costa-Frossard, Lucienne, Prefasi, Daniel, Maurino, Jorge

“…Introduction Neuromyelitis optica spectrum disorder (NMOSD) is associated with a reduced health-related quality of life (HRQoL). The purpose of this study was…”
Get full text

Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study by Coyle, Patricia K., Khatri, Bhupendra, Edwards, Keith R., Meca-Lallana, José E., Cavalier, Steve, Rufi, Pascal, Benamor, Myriam, Poole, Elizabeth M., Robinson, Miqun, Gold, Ralf

“…•Baseline characteristics of MS patients differed by region in Teri-PRO.•Teriflunomide improved treatment satisfaction regardless of baseline differences.•More…”
Get full text

Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis by Mutukula, Naresh, Man, Zhiqiu, Takahashi, Yuta, Iniesta Martinez, Francisca, Morales, Mariana, Carreon-Guarnizo, Ester, Hernandez Clares, Rocio, Garcia-Bernal, David, Martinez Martinez, Llanos, Lajara, Jeronimo, Nuñez Delicado, Estrella, Meca Lallana, Jose E., Izpisua Belmonte, Juan Carlos

“…•Pluripotent stem cells (hiPSCs) were generated from healthy individuals and patients with RRMS and PPMS.•All the generated hiPSC lines displayed the…”
Get full text

Consensus on early detection of disease progression in patients with multiple sclerosis by Meca-Lallana, José E., Casanova, Bonaventura, Rodríguez-Antigüedad, Alfredo, Eichau, Sara, Izquierdo, Guillermo, Durán, Carmen, Río, Jordi, Hernández, Miguel Ángel, Calles, Carmen, Prieto-González, José M., Ara, José Ramón, Uría, Dionisio F., Costa-Frossard, Lucienne, García-Merino, Antonio, Oreja-Guevara, Celia

“…Background Early identification of the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) can be challenging for…”
Get full text

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis by Comi, Giancarlo, Freedman, Mark S, Meca-Lallana, José E, Vermersch, Patrick, Kim, Byoung Joon, Parajeles, Alexander, Edwards, Keith R, Gold, Ralf, Korideck, Houari, Chavin, Jeffrey, Poole, Elizabeth M, Coyle, Patricia K

“…In this pooled, post hoc analysis of a phase 2 trial and the phase 3 TEMSO, TOWER, and TENERE clinical trials, long-term efficacy and safety of teriflunomide…”
Get full text

Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I) by Fernández, Óscar, Álvarez-Cermeño, José C, Arroyo-González, Rafael, Brieva, Lluís, Calles-Hernández, M Carmen, Casanova-Estruch, Bonaventura, Comabella, Manuel, de las Heras, Virginia, García-Merino, Juan A, Hernández-Pérez, Miguel A, Izquierdo, Guillermo, Meca-Lallana, José E, Muñoz-García, Delicias, Olascoaga, Javier, Oreja-Guevara, Celia, Prieto, José M, Ramió-Torrentà, Lluís, Rodríguez-Antigüedad, Alfredo, Romero-Pinel, Lucía, Sanchez, Fernando, Téllez, Nieves, Tintoré, Mar, Montalban, Xavier

“…The new insights presented at the 5th Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS…”
Get full text

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I) by Fernández, Óscar, Arnal-García, Carmen, Arroyo-González, Rafael, Brieva, Lluís, Calles-Hernández, M Carmen, Casanova-Estruch, Bonaventura, Comabella, Manuel, de Las Heras, Virginia, García-Merino, Juan A, Hernández-Pérez, Miguel A, Izquierdo, Guillermo, Matas, Elisabet, Meca-Lallana, José E, Mendibe-Bilbao, María del Mar, Muñoz-García, Delicias, Olascoaga, Javier, Oreja-Guevara, Celia, Prieto, José M, Ramió-Torrentà, Lluís, Rodríguez-Antigüedad, Alfredo, Saiz, Albert, Téllez, Nieves, Villar, Luisa M, Tintoré, Mar

“…The most relevant data presented at the 28th edition of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in October 2012…”
Get full text

Quantifying the patient's perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire by Meca-Lallana, José E, Maurino, Jorge, Pérez-Miralles, Francisco, Forero, Lucía, Sepúlveda, María, Calles, Carmen, Martínez-Ginés, María L, González-Suárez, Inés, Boyero, Sabas, Romero-Pinel, Lucía, Sempere, Ángel P, Meca-Lallana, Virginia, Querol, Luis, Costa-Frossard, Lucienne, Prefasi, Daniel, Gómez-Ballesteros, Rocío, Ballesteros, Javier

“…Background The assessment of self-reported outcomes in neuromyelitis optica spectrum disorder (NMOSD) is limited by the lack of validated disease-specific…”
Get full text

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study by Meca-Lallana, José E., Prieto González, José M., Caminero Rodríguez, Ana B., Olascoaga Urtaza, Javier, Alonso, Ana M., Durán Ferreras, Eduardo, Espinosa, Raúl, Dotor, Julio, Romera, Mercedes, Ares Luque, Adrián, Pérez Ruiz, Domingo, Calles, Carmen, Hernández, Miguel A., Hervás García, Miguel, Mendoza Rodríguez, Amelia, Berdei Montero, Yasmina, Téllez, Nieves, Herrera Varó, Nicolás, Sotoca, Javier, Presas-Rodríguez, Silvia, Querol Gutierrez, Luis A., Hervás Pujol, Mariona, Batlle Nadal, Jordi, Martín Ozaeta, Gisela, Gubieras Lillo, Laura, Martínez Yélamos, Sergio, Ramió-Torrentà, Lluís, Mallada Frechin, Javier, Belenguer Benavides, Antonio, Gascón-Giménez, Francisco, Casanova, Bonaventura, Landete Pascual, Lamberto, Berenguer, Leticia, Navarro, Laura, Gómez Gutierrez, Montserrat, Durán, Carmen, Rodríguez Regal, Ana, Álvarez, Elena, García-Estévez, Daniel A., López Real, Ana M., Llaneza González, Miguel A., Marzo Sola, María E., Sánchez-Menoyo, José L., Oterino, Agustín, Villaverde González, Ramón, Castillo-Triviño, Tamara, Álvarez de Arcaya, Amaya, Llarena, Cristina

“…Introduction Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing–remitting multiple…”
Get full text

Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology by Brieva, Luis, Estruch, Bonaventura Casanova, Merino, Juan Antonio García, Meca-Lallana, Virginia, Río, Jordi, Rodríguez-Antigüedad, Alfredo, Agüera, Eduardo, Ara, Jose Ramón, Luque, Adrián Arés, Garcia, Carmen Arnal, Blanco, Yolanda, Castillo-Triviño, Tamara, Costa-Frossard, Lucienne, González Platas, Montserrat, Pascual, Lamberto Landete, Llaneza-González, Miguel, Ginés, María Luisa Martínez, Matías-Guiu, Jorge, Meca-Lallana, José E, Bilbao, Mar Mendibe, Sempere, Angel Pérez, Romero-Pinel, Lucia, Saiz, Albert, Moral, Ester

“…•The increase in DMTs for MS complicates the decisions on initial and subsequent therapies for each patient.•This article collates 99 clinically relevant…”
Get full text

Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules by Fuentes-Rumí, Luna, Hernández-Clares, Rocío, Carreón-Guarnizo, Ester, Valero-López, Gabriel, Iniesta-Martinez, Francisca, Cabrera-Maqueda, Jose Maria, León-Hernández, Adelaida, Zamarro-Parra, Joaquín, Morales-Ortiz, Ana, Meca-Lallana, José E

“…•The rebound phenomenon, a period of increased disease activity, following natalizumab discontinuation is recognised but its incidence has not been well…”
Get full text